Pharmaceutical company MediciNova has started enrolling ALS patients in advanced stages of the disease into its Phase II clinical trial of MN-166, or ibudilast (see Aug 2014 news). The FDA recently approved the company’s amendment to expand the ongoing study in patients not using non-invasive ventilation (NIV) to include 60 advanced ALS patients on NIV support. MN-166 is a small molecule phosphodiesterase 4 and 10 inhibitor and a macrophage migration inhibitory factor inhibitor that suppresses pro-inflammatory cytokines and stimulates expression of neurotrophic factors. The current study is investigating the safety and tolerability of MN-166 when given as an adjunct to riluzole in people in early and late stage ALS.
Click here to read more.